{"schema_version":"secwatch.filing_event.v1","accession":"0001564590-23-003792","form_type":"8-K","ticker":"ACHV","cik":"0000949858","company_name":"ACHIEVE LIFE SCIENCES, INC.","filed_at":"2023-03-16T23:59:59+00:00","discovered_at":"2026-05-14T18:03:48.688871+00:00","generated_at":"2026-06-18T01:31:30.430116+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Achieve Life Sciences reports Q4/FY 2022 net loss $42.4M; cash $24.8M; phase 3/2 trial data due Q2 2023","bullets":["Cash, cash equivalents, and restricted cash totaled $24.8M as of Dec 31, 2022.","Net loss for FY 2022 was $42.4M; Q4 2022 net loss $11.2M.","Phase 3 ORCA-3 and Phase 2 ORCA-V1 top-line results expected in Q2 2023.","Closed $18.9M private placement in Nov 2022 to fund trials and working capital.","USPTO granted patent for cytisinicline mesylate salt formulation, expiring 2042."],"urls":{"canonical":"https://secwatch.observer/filing/0001564590-23-003792","json":"https://secwatch.observer/filing/0001564590-23-003792.json","markdown":"https://secwatch.observer/filing/0001564590-23-003792.md","text":"https://secwatch.observer/filing/0001564590-23-003792.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/949858/000156459023003792/0001564590-23-003792-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/949858/000156459023003792/achv-8k_20230316.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-18T01:31:30.430116+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}